The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Isa-VRd in older patients with/without frailty criteria: pooled analysis in newly diagnosed myeloma
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses the efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone (Isa-VRD) in older patients with newly diagnosed multiple myeloma (MM) with or without frailty criteria, presenting a pooled analysis of the IMROZ (NCT03319667) and a Phase Ib study (NCT02513186). Dr Ocio highlights that while the quadruplet regimen can be used for most patients, including those over 75 years old, caution is advised for frail patients over 75, for whom a triplet regimen may be more suitable. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
